MYSTIC, Conn. and DUBLIN, Feb. 7, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN) today announced that it is scheduled to participate in
the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
on Wednesday, February 16, 2011. Amarin’s participation includes
both a panel discussion on Cardiology at 7:45am ET and a company
presentation at 9:15am ET. The conference will be held at the
Roosevelt Hotel in New York City.
A live audio webcast of the presentation will be available at
the following URL:
http://www.wsw.com/webcast/leerink20/amrn
About AmarinAmarin Corporation plc is a clinical-stage
biopharmaceutical company with expertise in lipid science focused
on the treatment of cardiovascular disease. The Company’s lead
product candidate is AMR101, the active ingredient in which is
ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company
reported positive, statistically significant top-line results from
the MARINE trial, the first of its Phase 3 clinical trials of
AMR101. In the MARINE trial, AMR101 was investigated as a treatment
for very high triglycerides (>500 mg/dL). AMR101 is presently
being investigated in a second Phase 3 clinical trial, the ANCHOR
trial, for the treatment of patients on statin therapy with high
triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia.
The MARINE trial was, and the ANCHOR trial currently is, conducted
under Special Protocol Assessment (SPA) agreements with the U.S.
Food and Drug Administration (FDA). Amarin also has next-generation
lipid candidates under evaluation for preclinical
development.Investor Contact Information: Stephen SchultzInvestor
Relations and Corporate CommunicationsAmarin CorporationIn U.S.: +1
(860) 572-4979 x292
investor.relations@amarincorp.com Le
‘/>”/>
SOURCE